Intelligent Bio Solutions Inc. filings document a medical technology issuer commercializing rapid, non-invasive fingerprint sweat drug screening and reporting through periodic material-event disclosures. Recent 8-Ks cover operating results, preliminary revenue information, Regulation FD presentations, clinical study program updates tied to the Intelligent Fingerprinting Drug Screening System, and manufacturing disclosures for readers and lateral-flow test strips.
The filing record also includes capital-structure and governance subjects, including common stock issued through warrant exercises and an at-the-market offering agreement, restricted stock awards under the 2019 Long Term Incentive Plan and Australian Sub-Plan, and Nasdaq Capital Market bid-price compliance notices. These disclosures frame the company's product commercialization, regulatory pathway, equity compensation, share count and listing-status matters.
Intelligent Bio Solutions Inc. reported that it has regained compliance with Nasdaq’s minimum bid price listing rule. The company previously received notice that its common stock had closed below the required $1.00 per share for 30 consecutive business days, putting its Nasdaq Capital Market listing at risk under Listing Rule 5550(a)(2).
On January 7, 2026, Nasdaq’s Listing Qualifications Staff notified the company that it is back in compliance because the closing bid price of its common stock was at or above $1.00 per share for 14 consecutive business days from December 16, 2025 to January 6, 2026. Nasdaq has indicated that the matter is now closed.
Intelligent Bio Solutions Inc. reported that Nasdaq notified the company on December 15, 2025 that its common stock failed to meet the $1.00 minimum bid price for 30 consecutive business days, putting it out of compliance with Nasdaq’s Bid Price Rule. The notice does not immediately remove the stock from the Nasdaq Capital Market, and the company has until June 15, 2026 to regain compliance by maintaining a closing bid of at least $1.00 for 10 consecutive business days.
Nasdaq may grant a further 180-day compliance period if other listing standards are satisfied, but this is not assured, and the stock could become subject to delisting, with the company able to appeal to a Nasdaq Hearings Panel. To address the issue, the company filed a Certificate of Amendment to implement a 1-for-10 reverse stock split effective late on December 15, 2025, with shares trading on a split-adjusted basis on December 16, 2025.
Intelligent Bio Solutions Inc. is implementing a 1-for-10 reverse stock split of its common stock, effective at 11:59 p.m. Eastern Time on December 15, 2025.
At the effective time, every 10 issued and outstanding shares will be combined into 1 share, with the par value remaining $0.01. As a result, common shares outstanding will decrease from approximately 9,595,335 as of December 14, 2025 to approximately 959,533 immediately after the split, while authorized common shares will stay at 100 million.
Outstanding stock options, restricted stock units, warrants and the share reserve under the 2019 Plan will be adjusted proportionately. Split-adjusted shares are expected to begin trading on The Nasdaq Capital Market on December 16, 2025 under the symbol INBS with a new CUSIP number. No fractional shares will be issued; instead, holders will receive cash based on the average closing prices over the five trading days before the split. The company also provided post-split versions of recent share and loss-per-share data.
Intelligent Bio Solutions Inc. furnished a Form 8-K announcing financial results for the fiscal quarter ended September 30, 2025. The results were communicated via a press release attached as Exhibit 99.1. The company stated that the information is furnished, not filed, and will not be incorporated by reference into other filings unless expressly stated.
Intelligent Bio Solutions Inc. (INBS) reported results for the quarter ended September 30, 2025. Revenue was $1,111,797, up from $872,287, with gross profit of $518,291 and an improved gross margin of 46.6%. Government support income was $193,267. Operating expenses rose to $3,711,151, including $2,659,824 in SG&A, $486,169 in development and regulatory costs, and a $261,780 impairment.
The company recorded a net loss of $2,994,992 (loss per share $0.35). Cash and cash equivalents were $1,660,105, with a working capital deficit of $577,705. Management stated that these conditions raise substantial doubt about the company’s ability to continue as a going concern without additional funding.
INBS raised funds via equity: $3,332,646 net from July 2025 warrant inducements and $213,750 net through its ATM program during the quarter. Warrants outstanding totaled 7,935,928. As of November 10, 2025, 9,452,553 common shares were outstanding. Management reported material weaknesses in internal control over financial reporting and disclosed Nasdaq minimum bid price compliance risk.
Intelligent Bio Solutions Inc. furnished an update on business performance, announcing preliminary, unaudited revenue results for the fiscal first quarter ended September 30, 2025. The details are provided in a press release attached as Exhibit 99.1.
The disclosure is presented as information furnished under Item 2.02 and is not deemed “filed” for purposes of the Exchange Act, nor incorporated by reference unless expressly stated.
Intelligent Bio Solutions Inc. announced the addition of 33 new customer accounts during its fiscal first quarter for the period ended September 30, 2025. The update was furnished under Item 7.01 (Regulation FD) and accompanied by a press release filed as Exhibit 99.1.
The company listed its common stock under the symbol INBS on the Nasdaq Stock Market LLC. The disclosure was signed by Spiro Sakiris, Chief Financial Officer.
Intelligent Bio Solutions (INBS) reported results from its October 16 annual meeting. Stockholders approved an amendment to the 2019 Long Term Incentive Plan, increasing the share pool by 495,000 to 1,795,000 shares. They also approved, for Nasdaq Listing Rule 5635(d) purposes, the potential issuance of up to 4,147,616 shares upon warrant exercise.
Directors were elected and the appointment of UHY LLP as auditor for the fiscal year ending June 30, 2026 was ratified. Stockholders authorized a reverse stock split within a 1‑for‑2 to 1‑for‑10 range, at the Board’s discretion within 12 months, solely to help regain compliance with the Nasdaq Capital Market minimum bid price requirement. At the meeting, 4,482,941 shares voted, representing approximately 49.65% of the 9,028,712 shares outstanding as of September 11, 2025.
Intelligent Bio Solutions Inc. furnished a current report describing a press release about its regulatory plans. On September 26, 2025, the company announced an update to the timeline for its anticipated FDA 510(k) clearance for using its Intelligent Fingerprinting Drug Screening System to test for the opiate codeine. The press release with further details is attached as an exhibit to the report and is treated as furnished, not filed, under securities law.
INTELLIGENT BIO SOLUTIONS, INC. (INBS) filed an Form 8-K reporting a material event that attaches the Form of Amended Series H-1 Warrant as an exhibit. The filing lists Exhibit 4.1 as the amended warrant form and includes an Inline XBRL cover page data file. The document is signed by Spiro Sakiris, Chief Financial Officer.
The filing notifies stakeholders that the company has documented changes to the Series H-1 warrant in a formal amended warrant agreement, but it does not disclose the economic terms, number of warrants affected, exercise price, expiration, or any related cash or equity effects.